MustafaKhasrawMDFRACP FRCP

Oncology • Durham, NC

Professor | Medical Oncologist

Join to view full profile

Dr. Khasraw is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khasraw's full profile

Already have an account?

Office
200 Trent Dr
Durham, NC 27710

Education & Training

University of Groningen Faculty of Medical ScienceClass of 2001

Certifications & Licensure

NC State Medical License 2019 - 2025

Clinical Trials

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers Start of enrollment: 2008 Dec 01
Active, not recruiting
Phase 3
A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer Start of enrollment: 2012 Nov 01
Terminated
Not Applicable
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer Start of enrollment: 2013 Apr 01
Unknown status
Phase 2
A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas Start of enrollment: 2015 May 01
Unknown status
Phase 2
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Start of enrollment: 2019 Sep 30
Terminated
Phase 2
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM Start of enrollment: 2018 Feb 22
Active, not recruiting
Phase 2
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies Start of enrollment: 2020 Aug 04
Completed
Phase 1
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial Start of enrollment: 2024 Mar 21
Recruiting
Phase 2
Roles: Contact
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 Start of enrollment: 2024 May 01
Not yet recruiting
Phase 1
Roles: Contact
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 (SElf-Replicating RNA IL-12) Intratumoral Injection in Patients With Recurrent or Progressive High-Grade Glioma Start of enrollment: 2024 Oct 01
Not yet recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Leptomeningeal metastatic disease: new frontiers and future directions.
Ahmad Ozair, Hannah Wilding, Debarati Bhanja, Nicholas Mikolajewicz, Michael Glantz
Nature Reviews. Clinical Oncology. 2024-12-09
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.
Marco Gallus, Jacob S Young, Sarah Cook Quackenbush, Mustafa Khasraw, John de Groot
Neuro-Oncology. 2024-10-24
A brave new framework for glioma drug development.
Kelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, Marjolein Geurts, Timothy F Cloughesy
The Lancet. Oncology. 2024-10-01

Lectures

A randomized phase 2 trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM): Feasibility ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Clinical Trials Are Moving Out of the Lab and into People’s HomesFebruary 18th, 2021
Veliparib Is Well Tolerated When Added to Standard Treatment in Unmethylated MGMT Glioblastoma MultiformeNovember 23rd, 2019
Global Coalition to Design Adaptive Clinical Trial for GlioblastomaNovember 16th, 2015
Join now to see all

MustafaKhasrawMDFRACP FRCP

Dr. Khasraw is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.